Apogee's $350M offering; BiomX merges with Adaptive Phage
06 Mar 2024
Phase 1Phase 2
Plus, news about Telios Pharma and Celldex Therapeutics:
Another day, another public offering: Apogee Therapeutics is aiming to raise $350 million in a stock sale announced the same day that it shared Phase I data for its atopic dermatitis treatment in healthy volunteers that hints at potentially longer dosing intervals. — Jaimy Lee
BiomX merges with Adaptive Phage Therapeutics: The combined phage therapy biotech will have two Phase II assets: BX004 for chronic pulmonary infections in cystic fibrosis, and BX211 for diabetic foot osteomyelitis. BiomX also secured a $50 million private placement to advance the programs through clinical readouts in 2025. — Ayisha Sharma
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.